{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:38:56Z","timestamp":1781642336880,"version":"3.54.5"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Beverly Mitchell"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with advanced biliary tract cancers (BTCs) have poor prognoses and limited therapeutic options. Renin-angiotensin antagonists (ACE-I\/ARBs), statins, and aspirin may have potential anti-tumorigenic effects and decrease mortality per retrospective analyses in some solid tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy of ACE-Is\/ARBs, statins, and\/or aspirin concurrent to first-line systemic therapy in patients with advanced or metastatic BTC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult patients at University of Michigan with pathologic confirmation of BTC between January 2010 and December 2020 were included in this retrospective analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1140 patients who met eligibility, a total of 509 patients received one or more concomitant medication(s) of interest in conjunction with systemic therapy for advanced cancer. In the total cohort, the overall survival for locally advanced patients (N = 305) was 16.3 months (95% CI: 12.1-18.6), and metastatic patients (N = 512) 8.6 months (95% CI: 7.6-9.5); P &amp;lt; .0001. Within this concomitant medication cohort, patients with locally advanced stage (n = 132) experienced significantly longer progression-free survival (9.8 vs 4.5; P &amp;lt; 0.0001), and overall survival (17.4 vs 10.6; P &amp;lt; 0.0001) than those with metastatic (n = 297) cancer, respectively. Patients who received ACE-Is\/ARBs, statins, and\/or aspirin (n = 245) versus not (n = 264) concurrent with systemic anti-cancer therapy did not experience improved progression-free (5.5 vs 5.5 months; hazard ratio (HR) 1.1; P = 0.51), or overall survival (12.3 vs 12.6 months; HR 1.1; P = 0.18), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In contrast to prior studies, no progression free or overall survival benefit in patients with advanced BTC from concurrent use of ACE-I\/ARBs, statin, and\/or aspirin with systemic therapy was observed when assessed by BTC subtype or specific systemic therapy regimen.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyad063","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T15:28:44Z","timestamp":1681140524000},"page":"531-541","source":"Crossref","is-referenced-by-count":7,"title":["Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy"],"prefix":"10.1093","volume":"28","author":[{"given":"Valerie","family":"Gunchick","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"},{"name":"Rogel Cancer Center, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L","family":"McDevitt","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Michigan , Ann Arbor, MI , USA"},{"name":"Rogel Cancer Center, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Winslow","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M","family":"Zalupski","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"},{"name":"Rogel Cancer Center, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-1548","authenticated-orcid":false,"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"},{"name":"Rogel Cancer Center, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"issue":"10272","key":"2023060913503061000_CIT0001","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"2023060913503061000_CIT0002","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2009.27.4787","article-title":"Genetics of biliary tract cancers and emerging targeted therapies","volume":"28","author":"Hezel","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2023060913503061000_CIT0003","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/jco.2015.33.15_suppl.4009","article-title":"Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations","volume":"33","author":"Ross","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023060913503061000_CIT0004","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"2023060913503061000_CIT0005","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum Pathol"},{"issue":"11","key":"2023060913503061000_CIT0006","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.3390\/cancers12113370","article-title":"Biliary tract cancers: molecular heterogeneity and new treatment options","volume":"12","author":"Personeni","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"14","key":"2023060913503061000_CIT0007","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2023060913503061000_CIT0008","doi-asserted-by":"crossref","first-page":"LBA490","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.","volume":"41","author":"Shroff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"2023060913503061000_CIT0009","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J Clin Oncol"},{"issue":"0","key":"2023060913503061000_CIT0010","first-page":"EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"0","author":"Oh","journal-title":"NEJM Evidence"},{"key":"2023060913503061000_CIT0011","doi-asserted-by":"crossref","first-page":"174415","DOI":"10.1016\/j.ejphar.2021.174415","article-title":"Angiotensin II promotes primary tumor growth and metastasis formation of murine TNBC 4T1 cells through the fibroblasts around cancer cells","volume":"909","author":"Takiguchi","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2023060913503061000_CIT0012","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40425-018-0401-3","article-title":"Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy","volume":"6","author":"Xie","year":"2018","journal-title":"J ImmunoTher Cancer"},{"issue":"4","key":"2023060913503061000_CIT0013","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00280-017-3267-z","article-title":"The influence of TNF-\u03b1 and Ang II on the proliferation, migration and invasion of HepG2 cells by regulating the expression of GRK2","volume":"79","author":"Xu","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023060913503061000_CIT0014","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcp.2018.04.012","article-title":"Angiotensin II promotes pulmonary metastasis of melanoma through the activation of adhesion molecules in vascular endothelial cells","volume":"154","author":"Ishikane","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"2023060913503061000_CIT0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clinre.2011.06.008","article-title":"Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms","volume":"35","author":"Beyazit","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"2023060913503061000_CIT0016","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3892\/ijo_00000776","article-title":"Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells","volume":"37","author":"Okamoto","year":"2010","journal-title":"Int J Oncol"},{"key":"2023060913503061000_CIT0017","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.canlet.2018.07.021","article-title":"Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein","volume":"434","author":"Saikawa","year":"2018","journal-title":"Cancer Lett"},{"issue":"6","key":"2023060913503061000_CIT0018","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3892\/ijo.2017.4177","article-title":"Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest","volume":"51","author":"Samukawa","year":"2017","journal-title":"Int J Oncol"},{"issue":"15","key":"2023060913503061000_CIT0019","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1200\/JCO.2020.38.15_suppl.3074","article-title":"Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer","volume":"38","author":"Cantini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023060913503061000_CIT0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12885-022-09200-4","article-title":"Angiotensin blockade therapy and survival in pancreatic cancer: a population study","volume":"22","author":"Keith","year":"2022","journal-title":"BMC Cancer"},{"issue":"13","key":"2023060913503061000_CIT0021","doi-asserted-by":"crossref","first-page":"e6394e6394","DOI":"10.1097\/MD.0000000000006394","article-title":"Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies","volume":"96","author":"Sun","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"2023060913503061000_CIT0022","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000337979","article-title":"How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?","volume":"83","author":"Kim","year":"2012","journal-title":"Oncology (Huntingt)"},{"issue":"5","key":"2023060913503061000_CIT0023","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00432-014-1873-2","article-title":"The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients","volume":"141","author":"Nakai","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2023060913503061000_CIT0024","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","article-title":"Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy","volume":"135","author":"Wilop","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"2023060913503061000_CIT0025","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br J Cancer"},{"key":"2023060913503061000_CIT0026","doi-asserted-by":"crossref","first-page":"660943","DOI":"10.3389\/fonc.2021.660943","article-title":"The use of antihypertensive drugs as coadjuvant therapy in cancer","volume":"11","author":"Carlos-Escalante","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"2023060913503061000_CIT0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.HYP.0000024348.87637.6F","article-title":"Simvastatin prevents angiotensin II\u2013induced cardiac alteration and oxidative stress","volume":"40","author":"Delbosc","year":"2002","journal-title":"Hypertension"},{"issue":"4","key":"2023060913503061000_CIT0028","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/01.HYP.0000259737.43916.42","article-title":"Do statins reduce blood pressure?","volume":"49","author":"Strazzullo","year":"2007","journal-title":"Hypertension"},{"issue":"8","key":"2023060913503061000_CIT0029","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(99)80621-3","article-title":"Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension","volume":"75","author":"Straznicky","year":"1995","journal-title":"Am J Cardiol"},{"issue":"1","key":"2023060913503061000_CIT0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15420\/apc.2011:3:1:33","article-title":"Cross-talk between statins and the renin-angiotensin system","volume":"3","author":"Han","year":"2011","journal-title":"Asia-Pacific Cardiology"},{"issue":"3","key":"2023060913503061000_CIT0031","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1470320314531058","article-title":"Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins","volume":"15","author":"Drapala","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"1","key":"2023060913503061000_CIT0032","doi-asserted-by":"crossref","first-page":"20403","DOI":"10.1038\/s41598-019-56532-6","article-title":"Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis","volume":"9","author":"Chou","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"2023060913503061000_CIT0033","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41419-020-2466-4","article-title":"Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins","volume":"11","author":"Tutuska","year":"2020","journal-title":"Cell Death Disease"},{"issue":"10","key":"2023060913503061000_CIT0034","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12032-022-01733-9","article-title":"Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells","volume":"39","author":"O\u2019Grady","year":"2022","journal-title":"Med Oncol"},{"issue":"15_suppl","key":"2023060913503061000_CIT0035","doi-asserted-by":"crossref","first-page":"TPS3165","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3165","article-title":"A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies","volume":"37","author":"Telfah","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023060913503061000_CIT0036","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2021.03.028","article-title":"FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted","volume":"75","author":"Vallejo","year":"2021","journal-title":"J Hepatol"},{"issue":"20","key":"2023060913503061000_CIT0037","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.3390\/ijms21207588","article-title":"Atorvastatin augments gemcitabine-mediated anti-cancer effects by inhibiting yes-associated protein in human cholangiocarcinoma cells","volume":"21","author":"Kitagawa","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"23","key":"2023060913503061000_CIT0038","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1080\/15384101.2019.1676581","article-title":"Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response","volume":"18","author":"Zhang","year":"2019","journal-title":"Cell Cycle"},{"issue":"3","key":"2023060913503061000_CIT0039","first-page":"561","article-title":"Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells","volume":"39","author":"Kamigaki","year":"2011","journal-title":"Int J Oncol"},{"key":"2023060913503061000_CIT0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lfs.2016.04.018","article-title":"Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells","volume":"153","author":"Buranrat","year":"2016","journal-title":"Life Sci"},{"issue":"4","key":"2023060913503061000_CIT0041","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.31146","article-title":"Effect of statins on the risk of extrahepatic cholangiocarcinoma","volume":"72","author":"Lavu","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"2023060913503061000_CIT0042","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/08037059409102263","article-title":"Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients","volume":"3","author":"Magagna","year":"1994","journal-title":"Blood Press"},{"issue":"5","key":"2023060913503061000_CIT0043","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/HYPERTENSIONAHA.109.134825","article-title":"Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines","volume":"54","author":"Snoep","year":"2009","journal-title":"Hypertension"},{"issue":"15","key":"2023060913503061000_CIT0044","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/0008-5472.CAN-19-0762","article-title":"Are platelets the primary target of aspirin\u2019s remarkable anticancer activity?","volume":"79","author":"Lichtenberger","year":"2019","journal-title":"Cancer Res"},{"issue":"11","key":"2023060913503061000_CIT0045","first-page":"3091","article-title":"Inhibitory effect of aspirin on cholangiocarcinoma cells","volume":"18","author":"Boueroy","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"issue":"8","key":"2023060913503061000_CIT0046","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/bjc.2011.289","article-title":"Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?","volume":"105","author":"Langley","year":"2011","journal-title":"Br J Cancer"},{"issue":"49","key":"2023060913503061000_CIT0047","doi-asserted-by":"crossref","first-page":"41047","DOI":"10.1074\/jbc.M503713200","article-title":"Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression","volume":"280","author":"Kim","year":"2005","journal-title":"J Biol Chem"},{"key":"2023060913503061000_CIT0048","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.2147\/CMAR.S175212","article-title":"Advances in antitumor effects of NSAIDs","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"3","key":"2023060913503061000_CIT0049","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3317\/jraas.2003.023","article-title":"Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance","volume":"4","author":"Meune","year":"2003","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"10","key":"2023060913503061000_CIT0050","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2362.2003.01240.x","article-title":"Activation of p53 signalling in acetylsalicylic acid-induced apoptosis in OC2 human oral cancer cells","volume":"33","author":"Ho","year":"2003","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2023060913503061000_CIT0051","first-page":"383","article-title":"A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells","volume":"9","author":"Goel","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10240","key":"2023060913503061000_CIT0052","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"The Lancet"},{"issue":"1","key":"2023060913503061000_CIT0053","doi-asserted-by":"crossref","first-page":"e2032072","DOI":"10.1001\/jamanetworkopen.2020.32072","article-title":"Evaluation of aspirin use with cancer incidence and survival among older adults in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"4","author":"Loomans-Kropp","year":"2021","journal-title":"JAMA Network Open"},{"issue":"19","key":"2023060913503061000_CIT0054","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.3390\/cancers13194959","article-title":"Superior overall survival in patients with colorectal cancer, regular aspirin use, and combined wild-type PIK3CA and KRAS-mutated tumors","volume":"13","author":"Gebauer","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2023060913503061000_CIT0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3892\/ijo.2020.5165","article-title":"Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo","volume":"58","author":"Shi","year":"2021","journal-title":"Int J Oncol"},{"issue":"4","key":"2023060913503061000_CIT0056","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/hep.31879","article-title":"Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort","volume":"74","author":"Liao","year":"2021","journal-title":"Hepatology"},{"issue":"12","key":"2023060913503061000_CIT0057","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jamaoncol.2019.4328","article-title":"Association between aspirin use and biliary tract cancer survival","volume":"5","author":"Jackson","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023060913503061000_CIT0058","first-page":"941","article-title":"EMERSE: the electronic medical record search engine","volume":"2006","author":"Hanauer","year":"2006","journal-title":"AMIA Annu Symp Proc"},{"issue":"1","key":"2023060913503061000_CIT0059","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/curroncol28010044","article-title":"A population-based retrospective study of biliary tract cancers in Alberta, Canada","volume":"28","author":"Beaulieu","year":"2021","journal-title":"Current Oncology."},{"issue":"1","key":"2023060913503061000_CIT0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000479929","article-title":"Brain metastases from biliary tract cancer: a monocentric retrospective analysis of 450 patients","volume":"94","author":"Frega","year":"2018","journal-title":"Oncology (Huntingt)"},{"issue":"3","key":"2023060913503061000_CIT0061","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4143\/crt.2018.326","article-title":"Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin","volume":"51","author":"Hyung","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"2","key":"2023060913503061000_CIT0062","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.18632\/oncotarget.13731","article-title":"Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"2023060913503061000_CIT0063","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00535-018-1518-3","article-title":"Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy","volume":"54","author":"Suzuki","year":"2019","journal-title":"J Gastroenterol"},{"issue":"9","key":"2023060913503061000_CIT0064","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/bjc.2014.190","article-title":"Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer","volume":"110","author":"Fornaro","year":"2014","journal-title":"Br J Cancer"},{"issue":"9","key":"2023060913503061000_CIT0065","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.21873\/anticanres.11065","article-title":"No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer","volume":"36","author":"Nakai","year":"2016","journal-title":"Anticancer Res"},{"issue":"1","key":"2023060913503061000_CIT0066","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-017-3353-2","article-title":"Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients","volume":"80","author":"Kim","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023060913503061000_CIT0067","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3332\/ecancer.2022.1345","article-title":"Evaluation of prognostic factors in patients undergoing first-line chemotherapy for advanced biliary tract cancer: a retrospective analysis from a South American cancer centre","volume":"16","author":"Felismino","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"2023060913503061000_CIT0068","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.717397","article-title":"First line and second line chemotherapy in advanced cholangiocarcinoma and impact of dose reduction of chemotherapy: a retrospective analysis","volume":"11","author":"M\u00f6hring","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"2023060913503061000_CIT0069","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.21873\/anticanres.13445","article-title":"Radiotherapy or chemoradiation in unresectable biliary cancer: a retrospective study","volume":"39","author":"Bisello","year":"2019","journal-title":"Anticancer Res"},{"issue":"24","key":"2023060913503061000_CIT0070","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/cncr.32463","article-title":"Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes","volume":"125","author":"Lowery","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"2023060913503061000_CIT0071","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1136\/gutjnl-2018-317504","article-title":"Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink","volume":"68","author":"Liu","year":"2019","journal-title":"Gut"},{"issue":"8","key":"2023060913503061000_CIT0072","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","article-title":"Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis","volume":"45","author":"Yadav","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"2023060913503061000_CIT0073","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.28529","article-title":"Aspirin use and the risk of cholangiocarcinoma","volume":"64","author":"Choi","year":"2016","journal-title":"Hepatology"},{"issue":"12","key":"2023060913503061000_CIT0074","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/ajg.2014.327","article-title":"A new clinically based staging system for perihilar cholangiocarcinoma","volume":"109","author":"Chaiteerakij","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2023060913503061000_CIT0075","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.hpb.2018.08.004","article-title":"Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma","volume":"21","author":"Kommalapati","year":"2019","journal-title":"HPB"},{"issue":"5","key":"2023060913503061000_CIT0076","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamaoncol.2020.0122","article-title":"Questionable survival benefit of aspirin use in patients with biliary tract cancer","volume":"6","author":"Bergquist","year":"2020","journal-title":"JAMA Oncol"},{"key":"2023060913503061000_CIT0077","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canep.2018.08.009","article-title":"Comparison of cancer diagnosis recording between the Clinical Practice Research Datalink, Cancer Registry and Hospital Episodes Statistics","volume":"57","author":"Arhi","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"3_suppl","key":"2023060913503061000_CIT0078","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/jco.2014.32.3_suppl.303","article-title":"Effects of statin, aspirin, or metformin use on recurrence free and overall survival in patients with biliary tract cancer (BTC)","volume":"32","author":"McNamara","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023060913503061000_CIT0079","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1477-2574.2011.00340.x","article-title":"Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database","volume":"13","author":"Clark","year":"2011","journal-title":"HPB"},{"issue":"4","key":"2023060913503061000_CIT0080","first-page":"80","article-title":"Cholangiocarcinoma in Pacific islanders compared to Asians","volume":"80","author":"Shiosaki","year":"2021","journal-title":"Hawaii J Health Soc Welf"},{"key":"2023060913503061000_CIT0081","doi-asserted-by":"crossref","first-page":"597813","DOI":"10.3389\/fonc.2020.597813","article-title":"High response rate and prolonged survival of unresectable biliary tract cancer treated with a new combination therapy consisting of intraarterial chemotherapy plus radiotherapy","volume":"10","author":"Goto","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"2023060913503061000_CIT0082","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.gassur.2005.12.002","article-title":"Predictors of long-term survival in patients with gallbladder cancer","volume":"10","author":"Balachandran","year":"2006","journal-title":"J Gastrointest Surg"},{"issue":"40","key":"2023060913503061000_CIT0083","doi-asserted-by":"crossref","first-page":"e22292","DOI":"10.1097\/MD.0000000000022292","article-title":"Survival analysis of patients with primary gallbladder cancer from 2010 to 2015: a retrospective study based on SEER data","volume":"99","author":"Zhu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2023060913503061000_CIT0084","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.4143\/crt.2016.538","article-title":"Prognostic factors and scoring model for survival in metastatic biliary tract cancer","volume":"49","author":"Park","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"9","key":"2023060913503061000_CIT0085","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1158\/1055-9965.EPI-21-0265","article-title":"Incidence and mortality of cancers of the biliary tract, gallbladder, and liver by sex, age, race\/ethnicity, and stage at diagnosis: United States, 2013 to 2017","volume":"30","author":"Ellington","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prevent"},{"issue":"2","key":"2023060913503061000_CIT0086","doi-asserted-by":"crossref","first-page":"604274","DOI":"10.5604\/01.3001.0010.8659","article-title":"Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995-2014","volume":"17","author":"Antwi","year":"2018","journal-title":"Ann Hepatol"},{"issue":"1","key":"2023060913503061000_CIT0087","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","article-title":"Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database","volume":"16","author":"Yao","year":"2016","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"2023060913503061000_CIT0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CEJ.0000000000000402","article-title":"The incidence rates and survival of gallbladder cancer in the USA","volume":"28","author":"Jaruvongvanich","year":"2019","journal-title":"Eur J Cancer Prev"},{"issue":"6","key":"2023060913503061000_CIT0089","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00432-022-03942-1","article-title":"Meta-analysis of aspirin-guided therapy of colorectal cancer","volume":"148","author":"M\u00e4dge","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"2023060913503061000_CIT0090","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2017.72.3569","article-title":"Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival","volume":"35","author":"Hua","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/531\/50514572\/oyad063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/531\/50514572\/oyad063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T17:44:00Z","timestamp":1701971040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/6\/531\/7111748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":90,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,4,10]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad063","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,4,10]]}}}